相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients
Caihua Zhu et al.
IRISH JOURNAL OF MEDICAL SCIENCE (2023)
Donafenib in hepatocellular carcinoma
Rusi Chen et al.
DRUGS OF TODAY (2023)
Transarterial chemoembolization for hepatocellular carcinoma with vascular invasion
Shiro Miyayama et al.
BRITISH JOURNAL OF RADIOLOGY (2022)
Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress
Zachary J. Brown et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
Lin Zhang et al.
FRONTIERS IN IMMUNOLOGY (2022)
Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma - A Retrospective Study
Yashwant Patidar et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2022)
Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma
Yan-Jun Xiang et al.
HEPATOLOGY RESEARCH (2022)
Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
Mingyue Cai et al.
FRONTIERS IN IMMUNOLOGY (2022)
Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
Shuping Qu et al.
FRONTIERS IN ONCOLOGY (2022)
Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study
Ziqiang Han et al.
FRONTIERS IN ONCOLOGY (2022)
Assessment of efficacy and prognostic factors by Gelfoam for DEB-TACE in unresectable large hepatocellular carcinoma with portal vein tumor thrombus: a multi-center retrospective study
Guang Sheng Zhao et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2022)
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
Brett Marinelli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial
ZhiCheng Lai et al.
EUROPEAN JOURNAL OF CANCER (2022)
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study
Wei-Feng Qu et al.
BJS OPEN (2022)
Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma
Ahmed Montasser et al.
HISTOPATHOLOGY (2021)
Donafenib: First Approval
Susan J. Keam et al.
DRUGS (2021)
Current epidemiology in hepatocellular carcinoma
Peter Konyn et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)
Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
Diyang Xie et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Hai-Qiang Mai et al.
NATURE MEDICINE (2021)
The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
Patrizia Leone et al.
VACCINES (2021)
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
David J. Pinato et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma
Jinpeng Li et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2021)
Epidemiological and etiological variations in hepatocellular carcinoma
Evangelista Sagnelli et al.
INFECTION (2020)
A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
Xiaoyu Li et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Transcatheter Arterial Chemoembolisation Combined with Radiofrequency Ablation on Hepatocellular Carcinoma and Levels of Relevant Markers
Jia Feng et al.
JCPSP-Journal of the College of Physicians and Surgeons Pakistan (2020)
The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma
Shou Wu Lee et al.
JOURNAL OF DIGESTIVE DISEASES (2020)
2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights
Di-Yang Xie et al.
HEPATOBILIARY SURGERY AND NUTRITION (2020)
Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients
Jinzhang Chen et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Hepatocellular carcinoma: old friends and new tricks
Eunsun Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
Young Chang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Targeting angiogenesis for liver cancer: Past, present, and future
Xiao-Dong Zhu et al.
GENES & DISEASES (2020)
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Masatoshi Kudo et al.
GUT (2020)
Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals
Edward M. Russak et al.
ANNALS OF PHARMACOTHERAPY (2019)
Disease Burden of Hepatocellular Carcinoma: A Global Perspective
Mehmet Sayiner et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Ju Dong Yang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Epidemiology and Management of Hepatocellular Carcinoma
Laura Kulik et al.
GASTROENTEROLOGY (2019)
Recent developments with immunotherapy for hepatocellular carcinoma
Oliver Waidmann
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments
Mario Petrillo et al.
FUTURE ONCOLOGY (2018)
The diagnosis and treatment of hepatocellular carcinoma
Justin Hartke et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2017)
Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
Jack P. Silva et al.
HPB (2017)
Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis
XiuPing Zhang et al.
ONCOTARGET (2017)
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system
Kichang Han et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
Yozo Sato et al.
UPSALA JOURNAL OF MEDICAL SCIENCES (2013)
Transcatheter Chemoembolization of Unresectable Hepatocellular Carcinoma: Current Knowledge and Future Directions
Geert Maleux et al.
DIGESTIVE DISEASES (2009)
Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness
Adriana Sergio et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)